Moneycontrol PRO
HomeNewsBusinessCompaniesAdulterated drugs: SC dismisses PIL against Ranbaxy

Adulterated drugs: SC dismisses PIL against Ranbaxy

The PIL was filed against Ranbaxy for allegedly manufacturing and selling of the adulterated drug. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard and adulterated drugs.

June 25, 2013 / 18:39 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    The Supreme Court on Tuesday dismissed a PIL against Ranbaxy. The court in its order said that there is no evidence to show that the pharma giant manufactured substandard drugs. The apex court also said that the petitioner failed to bring in evidence against Ranbaxy.


    The PIL was filed against Ranbaxy for allegedly manufacturing and selling of the adulterated drug. The petitioner cited the pharma giant's case in the US where Ranbaxy USA admitted to selling substandard and adulterated drugs. The pharma giant has been asked to pay a fine of 500 million dollars.


    Ranbaxy has been facing the heat even in India with a few hospitals banning its drugs.


    The PIL has also sought sealing of all Ranbaxy's manufacturing units in India, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.

    first published: Jun 25, 2013 12:12 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347